Send me real-time posts from this site at my email

Floyd F. Petersen, a director of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), sells 500 shares.

Originally published on Best Stocks

Category: best stocks to buy now

On Monday, October 3 October 3, Floyd F. Petersen, a director of Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH), sold 500 shares of the business’s stock. A total of $14,295.00 worth of the stock was sold, with an average price of $28.59. Following the deal, the director now directly owns 88,108 shares of the company with a market value of approximately $2,519,007.72. You can access the legal document where the transaction was reported by visiting this URL. Deposit $100 and get a $110 to trade stocks
>>>>>>>>>>Open Account

Amphastar Pharmaceuticals (NASDAQ: AMPH) released its quarterly results on Monday, August 8. The quarterly earnings per share (EPS) were $0.33, $0.03 higher than the average $0.30 estimate by experts. In contrast to the consensus forecast of $118.17 million, the company’s sales for the quarter came in at $123.47 million. A return on equity of 18.51% and a net margin of 19.06% was reported by Amphastar Pharmaceuticals. For the same period the year prior, the company reported $0.21 EPS. Based on the predictions of equity research specialists, Amphastar Pharmaceuticals, Inc. is anticipated to have 1.46 earnings per share for the current fiscal year, based on the predictions of equities research specialists.
Hedge funds recently changed the proportion of the stock they were holding. First, investment management company Mesirow Equity & Fixed Income added a fresh $9,035,000 position in Amphastar Pharmaceuticals during the first quarter. In addition, during the first quarter, Hillsdale Investment Management Inc. made a new investment of $8,412,000 in Amphastar Pharmaceuticals. Second, state Street Corp. boosted its holding in Amphastar Pharmaceuticals by 16.6% during the second quarter. State Street Corp now owns 1,540,846 shares, valued at $53,606,000, after acquiring an additional 218,895 shares in the last three months. Third, Goldman Sachs Group Inc. grew its stake in Amphastar Pharmaceuticals by 183.2% during the second quarter. Goldman Sachs Group Inc. now owns 329,843 shares worth $11,475,000 after acquiring an additional 213,355 shares in the last quarter. Lastly, Castleark Management LLC raised its stake in Amphastar Pharmaceuticals by $6,702,000 during the second quarter. Currently, institutions own 63.11% of the stock.

The share price of Amphastar Pharmaceuticals rose $0.14 on Tuesday, reaching $28.54. The stock’s 50-day and 200-day moving averages are $31.24 and $34.22, respectively, and 440,334 shares typically exchange hands on a given day. The company’s market value is $1.40 billion, its price-to-earnings ratio is 16.03, and its beta value is 0.72. Amphastar Pharmaceuticals, Inc.’s low and high prices for the prior year were $18.12 and $44.46, respectively. The company’s debt-to-equity ratio is 0.15, its quick ratio is 2.69, its current ratio is 3.64, and its current ratio is 0.15, respectively.

Several equity analysts have recently issued reports on the company. Capital One Financial started covering Amphastar Pharmaceuticals in a research report on Friday, July 29. The company received an “overweight” rating from them, with a $44.00 price target. Amphastar Pharmaceuticals’ rating was raised from “hold” to “buy” on September 21 and 21. Shares of the business have received buy recommendations from three research analysts, while the stock has received a hold rating from one analyst. According to data from Bloomberg, the average target price for the company is $38.50, and the overall recommendation is “Moderate Buy.”

The biopharmaceutical company Amphastar Medications, Inc. develops, produces, distributes, and sells both brand-name and generic pharmaceutical injections, inhalations, and intranasal products in the United States, China, and France. The organization’s two primary business segments are API and finished pharmaceutical goods.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue